PHAT — Phathom Pharmaceuticals Inc
NASDAQ · Healthcare · Biotechnology
$9.39
-$0.18 (-1.88%)
Phathom Pharmaceuticals Inc (PHAT) is a biotechnology company listed on NASDAQ. It is led by Steven L. Basta M.B.A., based in 100 Campus Drive, Florham Park, NJ, United States, 07932, with about 427 employees. Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Latest reported PHAT revenue for 2025-09-30 was $49.5M. Net income was -$200.1M. Revenue was up 25.3% from 2025-06-30 to 2025-09-30. PHAT currently screens at market cap $622.7M.
Use this PHAT page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the PHAT quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the PHAT SEC filings page. Lician reads the product cache first so this HTML stays unique to Phathom Pharmaceuticals Inc even when a live quote feed is slow.
About Phathom Pharmaceuticals Inc
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
PHAT Key Statistics
Market Cap
$622.74M
Volume
588,434
Previous Close
$8.80
Day Range
$8.57 – $8.86
EPS
-$5.29
Revenue
$55.25M
Net Income
-$334.33M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+8001.5%
Profit Margin
-605.1%
Employees
427
PHAT Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $55.25M | $682.00K | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$334.33M | -$201.59M | -$197.72M | -$143.88M |
| EPS (Diluted) | -$5.29 | -$3.93 | -$5.05 | -$3.89 |
Total Assets
$378.32M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$297.26M
Operating Cash Flow
-$266.77M
Free Cash Flow
$0.00
Phathom Pharmaceuticals Inc Company Information
- CEO, President & Director
- Steven L. Basta M.B.A.
- Headquarters
- 100 Campus Drive, Florham Park, NJ, United States, 07932
- Website
- www.phathompharma.com
- Phone
- 877 742 8466
- IPO / Founded
- 2019-10-25
- Sector
- Healthcare
- Industry
- Biotechnology